Effect of Rosiglitazone on Bone Quality in a Rat Model of Insulin Resistance and Osteoporosis

OBJECTIVE: Rosiglitazone (RSG) is an insulin-sensitizing drug used to treat type 2 diabetes mellitus. The A Diabetes Outcome Progression Trial (ADOPT) shows that women taking RSG experienced more fractures than patients taking other type 2 diabetes drugs. These were not osteoporotic vertebral fractu...

Descripción completa

Detalles Bibliográficos
Autores principales: Sardone, Laura D., Renlund, Richard, Willett, Thomas L., Fantus, Ivan G., Grynpas, Marc D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2011
Materias:
Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219933/
https://www.ncbi.nlm.nih.gov/pubmed/21998400
http://dx.doi.org/10.2337/db10-1672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219933/
https://www.ncbi.nlm.nih.gov/pubmed/21998400
http://dx.doi.org/10.2337/db10-1672

Ejemplares similares